Tumor Suppressor Protein p53

• 

  Subject Areas on Research

  • "Wildcatting" for breakthroughs in urothelial cancer detection and management--a frustrating business. 
  • 5'-3'-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. 
  • A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. 
  • A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP. 
  • A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest. 
  • A high-throughput CRISPR interference screen for dissecting functional regulators of GPCR/cAMP signaling. 
  • A network of genetic events sufficient to convert normal human cells to a tumorigenic state. 
  • A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. 
  • A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. 
  • A single AT-GC exchange can modulate charge transfer-induced p53-DNA dissociation. 
  • A spatially and temporally restricted mouse model of soft tissue sarcoma. 
  • A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1. 
  • A topical antioxidant solution containing vitamins C and E stabilized by ferulic acid provides protection for human skin against damage caused by ultraviolet irradiation. 
  • ARID1A-mutated ovarian cancers depend on HDAC6 activity. 
  • ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. 
  • ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. 
  • AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. 
  • Aberrant expression of cell-cycle regulatory proteins in human mesenchymal neoplasia. 
  • Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. 
  • Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. 
  • Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells. 
  • Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. 
  • Accelerated decline in lung function in cigarette smokers is associated with TP53/HDM2 polymorphisms. 
  • Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. 
  • Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. 
  • Activation of extracellular signal-regulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1. 
  • Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. 
  • Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma. 
  • Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. 
  • Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway. 
  • Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. 
  • Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. 
  • Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. 
  • Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. 
  • Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. 
  • Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. 
  • Alveolar macrophage apoptosis and TNF-alpha, but not p53, expression correlate with murine response to bleomycin. 
  • An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. 
  • An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. 
  • An animal model of adolescent nicotine exposure: effects on gene expression and macromolecular constituents in rat brain regions. 
  • An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. 
  • Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation. 
  • Apoptosis and P53 induction in human lung fibroblasts exposed to chromium (VI): effect of ascorbate and tocopherol. 
  • Apoptotic DNA fragmentation factor maintains chromosome stability in a P53-independent manner. 
  • Application of an antibody biochip for p53 detection and cancer diagnosis. 
  • Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. 
  • Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. 
  • Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. 
  • Association between p53 Arg72Pro polymorphism and colorectal cancer risk: a meta-analysis. 
  • Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. 
  • Association of combined p73 and p53 genetic variants with tumor HPV16-positive oropharyngeal cancer. 
  • Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. 
  • Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. 
  • Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. 
  • Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. 
  • Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. 
  • Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. 
  • C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. 
  • CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways. 
  • Cancer clocks in tumourigenesis: the p53 pathway and beyond. 
  • Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. 
  • Cell cycle control and cancer. 
  • Cell cycle deregulation and xeroderma pigmentosum group C cell transformation. 
  • Cell type- and species-specific host responses to Toxoplasma gondii and its near relatives. 
  • Cellular gene expression in papillomas of the choroid plexus from transgenic mice that express the simian virus 40 large T antigen. 
  • Characterization of cell-cycle arrest by fumonisin B1 in CV-1 cells. 
  • Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. 
  • Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin. 
  • Charge modification at multiple C-terminal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking. 
  • Checkpoint controls and cancer. Introduction. 
  • Choline deficiency induces apoptosis in SV40-immortalized CWSV-1 rat hepatocytes in culture. 
  • Chromatin-bound p53 anchors activated Smads and the mSin3A corepressor to confer transforming-growth-factor-beta-mediated transcription repression. 
  • Chromium (VI) activates ataxia telangiectasia mutated (ATM) protein. Requirement of ATM for both apoptosis and recovery from terminal growth arrest. 
  • Chromium(VI) induces p53-dependent apoptosis in diploid human lung and mouse dermal fibroblasts. 
  • Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny. 
  • Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation. 
  • Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. 
  • Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. 
  • Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study. 
  • Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. 
  • Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. 
  • Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. 
  • Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study. 
  • Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. 
  • Commentary on "Participation of p53 Protein in the Cellular Response to DNA Damage". 
  • Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. 
  • Comprehensive profiling of amino acid response uncovers unique methionine-deprived response dependent on intact creatine biosynthesis. 
  • Compromised HOXA5 function can limit p53 expression in human breast tumours. 
  • Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. 
  • Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. 
  • Coupling of human DNA excision repair and the DNA damage checkpoint in a defined in vitro system. 
  • DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. 
  • DNA damage induces phosphorylation of the amino terminus of p53. 
  • DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. 
  • DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. 
  • DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. 
  • DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. 
  • Death-associated protein kinase 1 promotes growth of p53-mutant cancers. 
  • Development of novel targeted therapies in the treatment of malignant glioma. 
  • Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines. 
  • Direct photoresponsive inhibition of a p53-like transcription activation domain in PIF3 by Arabidopsis phytochrome B. 
  • Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. 
  • Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. 
  • Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. 
  • Do neuroendocrine cells come up large in small cell lung cancer? 
  • Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. 
  • Dosage-dependent requirements of Magoh for cortical interneuron generation and survival. 
  • Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. 
  • Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. 
  • E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. 
  • Editorial comment. 
  • Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse. 
  • Effective blue light photodynamic therapy does not affect cutaneous langerhans cell number or oxidatively damage DNA. 
  • Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. 
  • Eligible and not eligible studies in the recent meta-analysis about p53 polymorphism and breast cancer risk. 
  • Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. 
  • Enhancing the efficiency of direct reprogramming of human primary fibroblasts into dopaminergic neuron-like cells through p53 suppression. 
  • Environmental factors in relation to breast cancer characterized by p53 protein expression. 
  • Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. 
  • Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice. 
  • Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia. 
  • Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. 
  • Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans. 
  • Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. 
  • Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury. 
  • Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers. 
  • Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. 
  • Expression signatures of TP53 mutations in serous ovarian cancers. 
  • FAK overexpression and p53 mutations are highly correlated in human breast cancer. 
  • Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. 
  • Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. 
  • Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. 
  • Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. 
  • Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. 
  • G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. 
  • G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. 
  • Gene expression profiling and genetic markers in glioblastoma survival. 
  • Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. 
  • Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance. 
  • Genetic basis for p53 overexpression in human breast cancer. 
  • Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk. 
  • Genetically engineered human cancer models utilizing mammalian transgene expression. 
  • Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. 
  • Genome-wide association study in NSAID-induced acute urticaria/angioedema in Spanish and Han Chinese populations. 
  • Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 
  • Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. 
  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy. 
  • Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. 
  • Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. 
  • Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. 
  • Global re-wiring of p53 transcription regulation by the hepatitis B virus X protein. 
  • Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation. 
  • Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells. 
  • Growth factor modulation of p53-mediated growth arrest versus apoptosis. 
  • Gut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway. 
  • HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. 
  • HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. 
  • HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. 
  • HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest. 
  • HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. 
  • Haploinsufficiency for Core Exon Junction Complex Components Disrupts Embryonic Neurogenesis and Causes p53-Mediated Microcephaly. 
  • Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. 
  • High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction of DNA damage response, an activity mediated by E7's inactivation of pocket proteins. 
  • Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. 
  • Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: Inhibition of cdk2. 
  • Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. 
  • Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. 
  • Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. 
  • INK4a/ARF Expression Impairs Neurogenesis in the Brain of Irradiated Mice. 
  • Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. 
  • Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. 
  • Identification of a DNA Damage-Induced Alternative Splicing Pathway That Regulates p53 and Cellular Senescence Markers. 
  • Identification of prohibitin and prohibiton as novel factors binding to the p53 induced gene 3 (PIG3) promoter (TGYCC)(15) motif. 
  • Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. 
  • Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. 
  • Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. 
  • Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours. 
  • Immunohistochemical examination of an orbital alveolar soft part sarcoma. 
  • Immunohistochemical expression of mutant p53 oncogene in transitional mucosa adjacent to human colon cancer. 
  • Impact of age at diagnosis on racial disparities in endometrial cancer patients. 
  • In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity. 
  • Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. 
  • Induction of CD56 and TCR-independent activation of T cells with aging. 
  • Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. 
  • Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation. 
  • Inhibition of p53 Sulfoconjugation Prevents Oxidative Hepatotoxicity and Acute Liver Failure. 
  • Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. 
  • Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. 
  • Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. 
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. 
  • Injury promotes sarcoma development in a genetically and temporally restricted manner. 
  • Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. 
  • Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. 
  • Interactions of chromatin context, binding site sequence content, and sequence evolution in stress-induced p53 occupancy and transactivation. 
  • Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational control of human p53 mRNA. 
  • Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas. 
  • Ionizing radiation activates the ATM kinase throughout the cell cycle. 
  • Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. 
  • Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome. 
  • Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. 
  • LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. 
  • Lack of p53 induction in fish cells by model chemotherapeutics. 
  • Levels of p53 protein increase with maturation in human hematopoietic cells. 
  • Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. 
  • Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. 
  • Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. 
  • Linking the history of radiation biology to the hallmarks of cancer. 
  • Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. 
  • Long-term male-specific chronic pain via telomere- and p53‑mediated spinal cord cellular senescence. 
  • Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. 
  • Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells. 
  • Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate. 
  • Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. 
  • MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. 
  • MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. 
  • Macrophage migration inhibitory factor deficiency in chronic obstructive pulmonary disease. 
  • Maintenance of p53 alterations throughout breast cancer progression. 
  • Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. 
  • Manganese superoxide dismutase is a mitochondrial fidelity protein that protects Polγ against UV-induced inactivation. 
  • Mdm2 regulates cardiac contractility by inhibiting GRK2-mediated desensitization of β-adrenergic receptor signaling. 
  • Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. 
  • Melanoma proliferation and chemoresistance controlled by the DEK oncogene. 
  • Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype. 
  • Mesotheliomas induced in rats by the fibrous mineral erionite are independent from p53 alterations. 
  • Metabolic stress in autophagy and cell death pathways. 
  • Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization. 
  • Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 
  • Methods to generate genetically engineered mouse models of soft tissue sarcoma. 
  • Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. 
  • Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. 
  • Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. 
  • Molecular characterization of adenocarcinoma of the cervix. 
  • Molecular genetic and immunohistochemical analysis of the tumor suppressor genes Rb and p53 in palmar and aggressive fibromatosis. 
  • Molecular testing for endometrial cancer: An SGO clinical practice statement. 
  • More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. 
  • Morphologic and molecular genetic aspects of oligodendroglial neoplasms. 
  • Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). 
  • Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. 
  • Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. 
  • Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells. 
  • Mutant p53 as an Antigen in Cancer Immunotherapy. 
  • Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. 
  • Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. 
  • Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. 
  • Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. 
  • Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. 
  • Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma. 
  • Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. 
  • Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. 
  • Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. 
  • NAD+ modulates p53 DNA binding specificity and function. 
  • NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. 
  • NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma. 
  • NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. 
  • Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. 
  • Necrosis and apoptosis of tumor cells in embolized meningiomas: histopathology and P53, BCL-2, CD-68 immunohistochemistry. 
  • Need for clarification of data in the recent meta-analysis about p53 polymorphism and gastric cancer risk. 
  • Negative regulation of the tumor suppressor p53 gene by microRNAs. 
  • Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. 
  • Nephrotoxicity and hepatotoxicity induced by inhaled bromodichloromethane in wild-type and p53-heterozygous mice. 
  • Neuroendocrine differentiation of prostate cancer. 
  • Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. 
  • Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. 
  • Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. 
  • Obesity and altered angiogenic-related gene expression in endometrial cancer. 
  • Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells. 
  • On the TRAIL from p53 to apoptosis? 
  • Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. 
  • Oncogenic Signaling Pathways in The Cancer Genome Atlas. 
  • Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. 
  • Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. 
  • Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. 
  • Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. 
  • P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. 
  • P53, cell cycle control and apoptosis: implications for cancer. 
  • PFT-alpha inhibits antibody-induced activation of p53 and pro-apoptotic signaling in 1-LN prostate cancer cells. 
  • PI3K/Akt and apoptosis: size matters. 
  • PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. 
  • PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. 
  • Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events. 
  • Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy. 
  • Parc-ing p53 in the cytoplasm. 
  • Participation of p53 protein in the cellular response to DNA damage. 
  • Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. 
  • Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation. 
  • Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis. 
  • Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. 
  • Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging. 
  • Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment. 
  • Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor Histology. 
  • Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. 
  • Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. 
  • Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. 
  • Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer. 
  • Potentiation of signal transduction mitogenesis and cellular proliferation upon binding of receptor-recognized forms of alpha2-macroglobulin to 1-LN prostate cancer cells. 
  • Prevalence of pulmonary atypical alveolar cell hyperplasia in an autopsy population: a study of 100 cases. 
  • Prognostic factors for fibromatoses: a correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome. 
  • Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. 
  • Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. 
  • Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. 
  • Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. 
  • Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. 
  • Proliferation of Double-Strand Break-Resistant Polyploid Cells Requires Drosophila FANCD2. 
  • Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. 
  • Protecting the hedgerow: p53 and hedgehog pathway interactions. 
  • Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. 
  • RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer. 
  • RGS-GAIP-interacting protein controls breast cancer progression. 
  • RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence. 
  • RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. 
  • RNAi the natural way. 
  • Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. 
  • Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. 
  • Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas. 
  • Re: Jiang et al.: Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk (Urology 2010;76:765). 
  • Reactivation of Epstein-Barr Virus by HIF-1α Requires p53. 
  • Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. 
  • Regulation of mammalian horizontal gene transfer by apoptotic DNA fragmentation. 
  • Regulation of mast cell survival and function by tuberous sclerosis complex 1. 
  • Regulation of myeloid leukaemia by the cell-fate determinant Musashi. 
  • Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. 
  • Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. 
  • Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. 
  • Relation between p53 overexpression and established prognostic factors in breast cancer. 
  • Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. 
  • Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. 
  • Replicative senescence revisited. 
  • Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States). 
  • Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. 
  • Resection of adrenocortical carcinoma liver metastasis: is it justified? 
  • Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. 
  • Restoration of p53 function leads to tumour regression in vivo. 
  • Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. 
  • Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. 
  • Role of p53 in apoptosis. 
  • Sensitization of Endothelial Cells to Ionizing Radiation Exacerbates Delayed Radiation Myelopathy in Mice. 
  • Sensitization of Vascular Endothelial Cells to Ionizing Radiation Promotes the Development of Delayed Intestinal Injury in Mice. 
  • Separate pathways for p53 induction by ionizing radiation and N-(phosphonoacetyl)-L-aspartate. 
  • Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. 
  • Signal transduction. Three paths to stress relief. 
  • Signalling to p53: where does it all start? 
  • Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. 
  • Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. 
  • Skp2 deficiency inhibits chemical skin tumorigenesis independent of p27(Kip1) accumulation. 
  • Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis. 
  • Sonic hedgehog from pharyngeal arch 1 epithelium is necessary for early mandibular arch cell survival and later cartilage condensation differentiation. 
  • Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent. 
  • Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53. 
  • Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. 
  • Stacking the DEK: from chromatin topology to cancer stem cells. 
  • Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. 
  • Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. 
  • Structure and regulation of the mouse ing1 gene. Three alternative transcripts encode two phd finger proteins that have opposite effects on p53 function. 
  • Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. 
  • Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. 
  • Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. 
  • Survival analysis of presumptive prognostic markers among oligodendrogliomas. 
  • Systematic Analysis of Splice-Site-Creating Mutations in Cancer. 
  • TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. 
  • TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. 
  • TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. 
  • TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). 
  • TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. 
  • TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. 
  • TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. 
  • TRIM35-mediated degradation of nuclear PKM2 destabilizes GATA4/6 and induces P53 in cardiomyocytes to promote heart failure. 
  • Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. 
  • Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. 
  • Telomere dysfunction causes alveolar stem cell failure. 
  • The Cancer Genome Atlas expression profiles of low-grade gliomas. 
  • The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. 
  • The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. 
  • The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. 
  • The Genetic Basis of Hepatosplenic T-cell Lymphoma. 
  • The TP53 tumor suppressor and autophagy in malignant lymphoma. 
  • The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. 
  • The complexity of p53 modulation: emerging patterns from divergent signals. 
  • The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. 
  • The dichotomy of p53 regulation by noncoding RNAs. 
  • The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. 
  • The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability. 
  • The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase. 
  • The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. 
  • The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. 
  • The p53 Transactivation Domain 1-Dependent Response to Acute DNA Damage in Endothelial Cells Protects against Radiation-Induced Cardiac Injury. 
  • The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. 
  • The p53 tumor suppressor gene frequently is altered in gynecologic cancers. 
  • The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. 
  • The p53-dependent gamma-ray response of GADD45. 
  • The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. 
  • The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study. 
  • The role of Hipk2-p53 pathways in arsenic-induced autistic behaviors: A translational study from rats to humans. 
  • The role of p53 in cell-cycle control and apoptosis: implications for cancer. 
  • The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response. 
  • The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. 
  • Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. 
  • Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. 
  • Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. 
  • Tp53 Suppression Promotes Cardiomyocyte Proliferation during Zebrafish Heart Regeneration. 
  • Transcriptional biomarkers distinguish between vulnerable periods for developmental neurotoxicity of chlorpyrifos: Implications for toxicogenomics. 
  • Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. 
  • Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models. 
  • Tumor marker expression is predictive of survival in patients with esophageal cancer. 
  • Tumor-suppressor p53: implications for tumor development and prognosis. 
  • Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. 
  • Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. 
  • UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. 
  • Ubiquitylation of p53 by the APC/C inhibitor Trim39. 
  • Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. 
  • WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. 
  • WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. 
  • WRN helicase is a synthetic lethal target in microsatellite unstable cancers. 
  • Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma. 
  • Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. 
  • Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer. 
  • Wild-type p53: tumors can't stand it. 
  • Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. 
  • Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. 
  • XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. 
  • Yin Yang 1 Promotes Thymocyte Survival by Downregulating p53. 
  • ZTF-8 interacts with the 9-1-1 complex and is required for DNA damage response and double-strand break repair in the C. elegans germline. 
  • [The effect of adenovirus-mediated wild-type p53 expression on the growth of human pancreatic carcinoma cell line cells]. 
  • bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. 
  • hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation. 
  • hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. 
  • mILC-ing the mouse mammary gland: A model for invasive lobular carcinoma. 
  • mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK. 
  • p21 protects "Super p53" mice from the radiation-induced gastrointestinal syndrome. 
  • p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. 
  • p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. 
  • p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. 
  • p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. 
  • p53 Regulates Progenitor Cell Quiescence and Differentiation in the Airway. 
  • p53 alterations in all stages of breast cancer. 
  • p53 and ATM: cell cycle, cell death, and cancer. 
  • p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. 
  • p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. 
  • p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. 
  • p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. 
  • p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. 
  • p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. 
  • p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. 
  • p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study. 
  • p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. 
  • p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice. 
  • p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. 
  • p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. 
  • p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. 
  • p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). 
  • p53 regulates the expression of the tumor suppressor gene maspin. 
  • p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. 
  • p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. 
  • p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. 
  • p53-dependent control of transactivation of the Pen2 promoter by presenilins. 
  • p53-dependent induction of heat shock protein 27 (HSP27) expression. 
  • p53: a two-faced cancer gene. 
  • p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. 
  • p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. 
  • p73 G4C14-to-A4T14 gene polymorphism and interaction with p53 exon 4 Arg72Pro on cancer susceptibility: a meta-analysis of the literature. 
• 

  Keywords of People

  • Badea, Cristian Tudorel, Professor in Radiology, Biomedical Engineering
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Ciofani, Maria, Associate Professor of Immunology, Cell Biology
  • Clyde, Merlise, Professor of Statistical Science, Statistical Science
  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Cell Biology
  • Luftig, Micah Alan, Associate Professor of Molecular Genetics and Microbiology, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Yan, Hai, Adjunct Professor of Pathology, Pathology